Drug profile · INN
ravulizumab-cwvz
ULTOMIRIS
ravulizumab-cwvz (ULTOMIRIS) is a complement c5 inhibitor. Route of administration: injection. Current US regulatory status: approved.
Drug details — ravulizumab-cwvz
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
ravulizumab-cwvz (ULTOMIRIS) is a complement c5 inhibitor. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Complement C5 inhibitor
Primary target: Complement C5
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is ravulizumab-cwvz?
ravulizumab-cwvz (ULTOMIRIS) is a complement c5 inhibitor. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for ravulizumab-cwvz?
ULTOMIRIS is a marketed brand name for ravulizumab-cwvz. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ravulizumab-cwvz?
ravulizumab-cwvz has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.